Recruiting

Guselkumab

Sponsor:

UCLA

Code:

NCT05858632

Conditions

Psoriasis of Scalp

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Guselkumab

Study Details

Brief summary:

This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.

Conditions

Psoriasis of Scalp

Study ID

NCT05858632

Start date

Jul 1, 2023

Status verified date

Jun, 2026

Completion date

Jun 30, 2028

Anticipated

Primary completion date

Jun 30, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria: possess a PSSI (psoriasis scalp severity index) of ≥12

Exclusion Criteria:

1. taking systemic immunosuppressives in the last 4 weeks
2. pregnancy
3. severe immunodeficiency (either from genetic or infectious causes).
4. tuberculosis or other active serious infection
5. active systemic malignancy.
6. breast-feeding
7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
8. Males who are trying to conceive

\-

Study Design

Enrollment

10 participants

Anticipated

Intervention Model

Single group

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: Guselkumab treatment

Guselkumab treatment for \~ 9 months

Interventions

Guselkumab

Guselkumab treatment for \~ 9 months

Primary outcome measure

  • Change in psoriasis scalp severity index score (PSSI) [ Time Frame: baseline and 9 months ]

Central Contacts and Locations

Central contacts

Jeffrey Cheng, MD, PhD

415 575 0524rashes@ucsf.edu

Locations

University of California San Francisco

Recruiting

San Francisco, California, United States, 94115

Contacts

Jeffrey Cheng, MD, PhD

415-575-0524rashes@ucsf.edu

More Information

Sponsor

University of California, San Francisco

Last update posted

Jun 4, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-06-04.